Nerlynx™ (neratinib) is a tyrosine kinase inhibitor indicated for the treatment of adult...
- Find out how pharma is fighting respiratory illnesses in the latest Pharma Technology Focus
- FDA accelerated review denial is a blow to Spectrum’s poziotinib
- Poxel closes enrolment in TIMES 2 trial of Imeglimin in Japan
- Cocrystal Pharma to study hepatitis C drug in Hong Kong
- Allergan assesses brazikumab in two clinical programmes for IBD
May’s top news stories
Novartis reported that the first clinical trial in its Phase III PLATINUM programme for QMF149 has met primary and key secondary endpoints in people with inadequately controlled asthma; and The National Institute of Allergy and Infectious Diseases (NIAID) has reported findings from a Phase I/II clinical trial of Okairos’ AdCh3NSmut1/MVA-NSmut vaccine. Drugdevelopment-technology.com wraps up the key headlines from May 2019.
Alnylam completes enrolment for ILLUMINATE-A study of lumasiran
Alnylam Pharmaceuticals has completed enrolment for its ILLUMINATE-A Phase III study of lumasiran to treat adults and children with primary hyperoxaluria type 1 (PH1).
AstraZeneca says Calquence prolongs CLL patients’ lifespan
AstraZeneca has said that the use of Calquence (acalabrutinib) significantly prolonged the time patients live without progression of disease in relapsed or refractory chronic lymphocytic leukaemia (CLL).
Boehringer and OSE dose first patient in Phase I trial of BI 765063
Boehringer Ingelheim and OSE Immunotherapeutics have dosed the first patient in a Phase I clinical trial of BI 765063 to treat patients with advanced solid tumours.
Chi-Med to end surufatinib’s Phase III SANET-ep trial early
Hutchison China MediTech (Chi-Med) has reported positive data from interim analysis of the pivotal Phase III SANET-ep clinical trial of surufatinib in patients with advanced non-pancreatic neuroendocrine tumours in China.
Noveome doses first subject in corneal epithelial defects trial
Noveome Biotherapeutics has started dosing patients in a Phase II clinical trial of topical ocular delivery of ST266 to treat persistent corneal epithelial defects (PEDs).
Incyte reports positive results from trial of ruxolitinib to treat vitiligo
Incyte has reported positive results from a Phase II trial of ruxolitinib cream for the treatment of adult patients aged 18 to 75 with vitiligo, a chronic, immune-mediated skin disease.
Concert Pharmaceuticals to launch Phase II schizophrenia trial
Concert Pharmaceuticals has revealed plans to initiate a Phase II clinical trial of CTP-692 as an adjunctive treatment for schizophrenia, based on positive data from Phase I programme.
Novartis’ Cosentyx shows efficacy in psoriatic arthritis trial
Novartis has announced that the Phase IIIb MAXIMISE clinical trial of its Cosentyx (secukinumab) drug met primary and key secondary endpoints in patients with psoriatic arthritis (PsA).
Lumosa to assess stroke drug in Phase II clinical trial
Taiwan-based Lumosa Therapeutics is set to launch a Phase II proof of concept clinical trial to evaluate its drug candidate LT3001 in patients with acute ischemic stroke (AIS).
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.